MedCity News January 7, 2026
The weight loss market is at yet another inflection point. The euphoria of the past three years is now confronting the realities of how obesity medications will scale to address an epidemic that impacts over 1 billion people globally.
In 2025, we witnessed just how dynamic the weight loss market can be in the era of GLP-1s. While Ozempic and Wegovy from NovoNordisk dominated in 2023 and 2024, 2025 was dominated by the rise and fall of compounding pharmacies, pricing pressure, and rise of Eli Lilly’s Mounjaro and Zepbound, erasing NovoNordisk’s market cap gains over the previous two years. In 2026, the conversation will shift again and will center around three questions that will shape the next decade in the...
Today's Sponsors
Today's Sponsor